Business
pSivida VP of Research to Discuss Company’s Protein and Antibody Sustained Delivery System at 5th Ocular Diseases and Drug Development Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida VP of Research to discuss company's protein and antibody sustained delivery system at upcoming Ocular diseases and drug conference.
Customer Survey Shows High Satisfaction Rate with ReVision Optics’ Near Vision Inlay for Presbyopia
LAKE FOREST, Calif.--(BUSINESS WIRE)--ReVision Optics®, Inc. (RVO), a leader in implantable inlay technology to treat presbyopia, reported a high level of satisfaction from a group of 58 patients treated for presbyopia at the Ultralase Clinics in the United Kingdom with the Company’s proprietary Vue+® near vision inlay. Mark Wevill, M.D., MBChB, FRCSEd, FCS(SA), presented the data at the 2012 ACOS Femto and Presby Ophthalmic Solutions Cataract and Refractive Surgery Symposium (PresbyOscars)
Sprint Launches Code Factory Mobile Accessibility Application for Free to Android Users Who Are Blind or Have Low Vision
SAN DIEGO--(BUSINESS WIRE)--Free app is now available, making Android smartphones more accessible for postpaid and no-contract Sprint customers.
OptiMedica Begins U.S. Shipments of the Catalys™ Precision Laser System; First U.S. Patients Treated at Mann Eye Institute, Houston
SANTA CLARA, Calif.--(BUSINESS WIRE)--OptiMedica begins shipping the Catalys Precision Laser System for cataract surgery in the U.S. First U.S. patients have been treated at Mann Eye Institute in Houston.
Status of Strategic Partnership Discussions Related to RGN-259 Ophthalmic Eye Drop
ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) is updating stockholders on the status of strategic discussions related to its ophthalmic drug candidate, RGN-259. Since data related to its Phase 2 dry eye clinical trial was released in November showing that RGN-259 had statistically significant benefits over placebo in certain signs and symptoms of dry eye syndrome, the company has been directly engaged in licensing.
pSivida Corp. to Hold Monday November 14 Conference Call to Discuss Complete Response Letter for ILUVIEN® for DME and pSivida’s Product Pipeline
WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida to hold conference call Monday to discuss product pipeline and CRL from FDA for ILUVIEN
OPKO Announces Sale of Ophthalmic Instrumentation Business
MIAMI--(BUSINESS WIRE)--OPKO Health, Inc. (NYSE: OPK) has agreed to sell its ophthalmic instrumentation business to OPTOS, Inc., a subsidiary of Optos plc, a leading and rapidly growing medical technology company engaged in the design, development, manufacture and marketing of devices to image the retina of the eye.
AGTC Receives Grant from the Foundation Fighting Blindness for Pre-Clinical Study of Gene Therapy for Eye Disease
GAINESVILLE, Fla.--(BUSINESS WIRE)--AGTC receives significant grant funding from the Foundation Fighting Blindness to develop treatment for genetic eye disease, XLRS, causing blindness in young boys.
Acucela and Otsuka Pharmaceutical Announce the Initiation of a Phase 1/2 Clinical Trial for OPA-6566 in Patients with Open-angle Glaucoma or Ocular Hypertension
SEATTLE & TOKYO--(BUSINESS WIRE)--Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, and Otsuka Pharmaceutical Co., Ltd., today announced the initiation of a Phase 1/2 clinical trial for OPA-6566. OPA-6566, an adenosine A2a receptor agonist, is being developed as an ophthalmic solution to reduce intraocular pressure in open-angle glaucoma (OAG) or ocular hypertension patients. OPA-6566 was discovered by Otsuka. The compound offers
SARcode Bioscience Completes $44 Million Series B Financing
SARcode Bioscience, Inc., a privately-held biopharmaceutical company, announced today the completion of a $44 million Series B private equity financing. The financing round was led by Sofinnova Ventures and was augmented by the additional backing of Rho Ventures and existing investors Alta Partners and Clarus Venture Partners."We believe that SARcode is uniquely positioned to make significant breakthroughs in the treatment of dry eye that could improve therapeutic options for millions of patient...
PowerVision Adds Medtronic as a Strategic Investor
PowerVision, Inc., a private company developing an accommodating intraocular lens, announced that it had added Medtronic to its list of investors in a recent closing of its Series C financing.
Transcend Medical Closes $51M Series B Financing
Transcend Medical, Inc., an ophthalmic device company dedicated to developing minimally invasive glaucoma therapies, announced the closure of its second tranche, bringing the total of Series B to $51M.
LensAR Focuses On $2M of $7M Offering for Laser 3D Imaging Tech
Orlando-based LensAR has raised $2 million of a targeted $7 million offering, according to a regulatory filing. The company is developing and commercializing laser and 3D imaging technology for refractive cataract surgery. The company raised $7 million in equity in July 2010 and $7.1 million in August 2009.
EyeMed Vision Care Expands Member Wellness Focus with Diabetic Eye Care Benefit
MASON, Ohio--(BUSINESS WIRE)--EyeMed Vision Care introduces a new Diabetic Eye Care benefit that provides follow-up care and supplementary diagnostic testing for patients with diabetes, a leading cause of adult blindness.
Neurotech’s NT-501 Implant Slows Vision Loss in Patients with Geographic Atrophy Associated with Dry AMD as Reported in PNAS
LINCOLN, R.I.--(BUSINESS WIRE)--Neurotech announced that it was reported in PNAS that its product candidate NT-501 slowed progression of vision loss in patients with geographic atrophy associated with dry AMD in a Phase 2 study.
Alcon Posts Solid Fourth Quarter Financial Results
HUENENBERG, Switzerland--(BUSINESS WIRE)--Alcon, Inc. (NYSE:ACL) reported that global sales rose 5.7 percent to $1.81 billion for the fourth quarter of 2010. Revenue from acquisitions added 100 basis points to sales growth in the quarter, while foreign currency fluctuations reduced reported sales growth by 20 basis points. Excluding these two factors, the organic sales growth rate was 4.9 percent. Net earnings for the fourth quarter of 2010 rose 13.8 percent to $521 million, or $1.71 per diluted
Research and Markets: Ophthalmic Devices Market Outlook in Japan to 2016 – Vision Care, Cataract and Refractive Surgery Devices and Others
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/885688/ophthalmic_devices) has announced the addition of GlobalData's new report "Ophthalmic Devices Market Outlook in Japan to 2016 - Vision Care, Cataract and Refractive Surgery Devices and Others" to their offering. Ophthalmic Devices Market Outlook in Japan to 2016 - Vision Care, Cataract and Refractive Surgery Devices and Others provides key market data on the Japan ophthalmic devices market.
Research and Markets: Ophthalmic Devices Market Outlook in the United States (US) to 2016 – Vision Care, Cataract and Refractive Surgery Devices and Others
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/e86f8c/ophthalmic_devices) has announced the addition of GlobalData 's new report "Ophthalmic Devices Market Outlook in the United States (US) to 2016 - Vision Care, Cataract and Refractive Surgery Devices and Others" to their offering.
Research and Markets: Ophthalmic Devices Market Outlook in India to 2016 – Vision Care, Cataract and Refractive Surgery Devices and Others
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/fb0df2/ophthalmic_devices) has announced the addition of GlobalData's new report "Ophthalmic Devices Market Outlook in India to 2016 - Vision Care, Cataract and Refractive Surgery Devices and Others" to their offering. Ophthalmic Devices Market Outlook in India to 2016 - Vision Care, Cataract and Refractive Surgery Devices and Others provides key market data on the India ophthalmic devices market
Company Profile for Acucela Inc.
--(BUSINESS WIRE)--Acucela Inc. is a clinical-stage biotechnology company focused on leveraging promising science in visual cycle modulation (VCM) to develop new methods for treating blinding eye diseases that affect tens of millions of people worldwide.
Subscribe
